RAPS Rivaroxaban in Antiphospholipid Syndrome (APS) - a Prospective, Randomized Controlled

SEPTEMBER 21, 2016 – WEDNESDAY – PRECONGRESS BOSPHORUS LUPUS LECTURES Moderators Doruk Erkan (USA), Murat Inanc (Turkey) Room Hall A Opening Remarks 8.30 am Doruk Erkan (USA) & Murat Inanc (Turkey) Clinical Manifestations: What Do We Understand 8.45 am Better? Michelle Petri (USA) Quality of Life I: How to Assess the Impact of 9.30 am Disease? Paul Fortin (Canada) Quality of Life II: How to Assess and Prevent 10.00 am Cardiovascular Disease? Ian Bruce (UK) 10.30 am Coffee break Is it Possible to Prevent Organ Damage? 11.00 am Mary-Carmen Amigo (Mexico) Lupus & Pregnancy: Critical Issues and Common 11.30 am Pitfalls Roger Levy (Brazil) Lunch and Case Discussions

 Group 1 Moderators - Paul Fortin & Murat Inanc 12.15 pm  Group 2 Moderators - Richard Furie & Doruk Erkan  Group 3 Moderators - Roger Levy & Seza Ozen Treatment I: Present Options & Challenges 1.30 pm Michelle Petri (USA) Treatment II: Linking Lupus Pathogenesis to 2.30 pm Drug Development Richard Furie (USA) 3.30 pm Coffee break Round Table 4.00 pm Group Discussion 4.45 Wrap-up/Closing 5.00 Doruk Erkan (USA) & Murat Inanc (Turkey)

Sponsored by an Unrestricted Educational Grant from GSK

SEPTEMBER 21, 2016 – WEDNESDAY EVENING OPENING GALA Room TBD Congress Opening Remarks  Doruk Erkan (USA) Chair, 15th International Congress on aPL  Murat Inanc (Turkey) President, Turkish Society of Rheumatology  Ahmet Muzaffer Demir (Turkey) President, Turkish Society of Hematology  Hasan Yazici (Turkey) Honorary Chair, 15th International Congress on aPL  Michael D Lockshin (USA) Honorary Chair, 15 International Congress on aPL

SEPTEMBER 22, 2016 – THURSDAY MORNING MEET THE EXPERT SESSIONS Antiphospholipid Antibody Lupus Anticoagulant Test: Lupus Anticoagulant Test: Antiphospholipid Antibody ELISA Tests: ELISA Tests: Technical Technical Aspects and Technical Aspects and Technical Aspects and Interpretation Aspects and Interpretation Interpretation (Turkish) Interpretation 7-8 am Maria Laura Bertolaccini (UK) (Turkish) Reyhan Diz Kucukkaya Ian Mackie (UK) Room: TBD Bahar Artim Esen (Turkey) (Turkey) Room: TBD Room: TBD Room: TBD

SEPTEMBER 22, 2016 – THURSDAY MORNING SESSIONS MAIN SESSION 1 DEEP DIVE SESSION 1 Origin of Antiphospholipid Antiphospholipid Syndrome Treatment Trends Antibodies Task Force Report Philip G de Groot (Netherlands), Moderator Danieli Andrade (Brazil), Maria Tektonidou Moderators Rohan Willis (USA) s (Greece) Room Hall A Room Hall B Introduction and the Role of Introduction & Summary of the 2013 Task Force Innate/Adaptive Immunity in Report 8.00 am aPL Production 8.00 am Maria Tektonidou (Greece) Rohan Willis (USA) The Role of Infection in aPL Is There a Role for Anti-peptide Therapy in APS? Production 8.25 am 8.10 am Anisur Rahman (UK) Miri Blank (Israel) Microbiata and APS What is New in Anti-complement Therapy in APS? Martin Kriegel (USA) (Online 8.50 am 8.30 amDanieli Andrade (Brazil) Presentation) Is Mechanistic Target of Rapamycin (mTOR) Natural Antibodies Inhibition an option in APS? 9.15 am Philip G de Groot (Netherlands) 8.50 am Guillaume Canaud (France) Statins in APS – Where do we stand? 9.10 amMaria Cuadrado (UK) Other Potential Future Treatment Targets in APS Group Conclusions 9.40 am 9.25 amMaria Gerosa (Italy) Closing Remarks and Future Directions 9.40 amDanieli Andrade (Brazil) 9.45 am Coffee Break, Exhibition, and 9.45 am Coffee Break, Exhibition, and Poster Discussions 10.30 am Poster Discussions 10.30 am

MAIN SESSION 2 DEEP DIVE SESSION 2 Mechanisms of Antiphospholipid International & National Collaborative Research Efforts in Antibody-mediated Thrombosis Antiphospholipid Syndrome Moderator Ahmet Gul (Turkey), Steve Krilis Moderator Doruk Erkan (USA), Ronald Derksen (Netherlands) s (Australia), Rohan Willis (USA) s Room Hall A Room Hall B 10.30 am General Review - aPL-mediated 10.30 am APS ACTION 6-year Anniversary & Thrombosis “Hydroxychloroquine Trial” Rohan Willis (USA) Doruk Erkan (USA) The Role of Post-Translational Strategies to Recruit Patients for Rare Diseases, Modification of β GPI in 2 Curbside Consultation, and Immunity 10.50 am aPL-mediated Thrombosis 11.00 am Oral Alpan (USA) Steve Krilis (Australia) Cell Signaling Pathways in aPL-mediated Update on European Forum on Antiphospholipid 11.10 am Thrombosis 11.30 am Antibodies Philip G de Groot (Netherlands) Denis Wahl (France) The Central Role of Inflammation in Lessons Learned from a National APS Registry aPL-mediated Thrombosis 11.30 am 11.50 amLjudmila Stojanovich (Serbia) Jason Knight (USA) The Role of Coagulation Pathways in 11.50 am aPL-mediated Thrombosis 12.10 pm Group Conclusions Hannah Cohen (UK) 12.10 pm Group Conclusions 12.15 pm 12.15 pm Lunch Break & Satellite Symposium Lunch Break & Satellite Symposium 1.30 pm 1.30 pm *A Joint Session with Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APSACTION)

SEPTEMBER 22, 2016 – THURSDAY NOON SATELLITE SYMPOSIUM The Future of Antiphospholipid Antibody Testing Moderators Maria Laura Bertolaccini (UK), Ian Mackie (UK) Room HALL A Opening Remarks 12.15 pm Maria Laura Bertolaccini (UK), Hannah Cohen (UK) The Value of Microparticle Chemiluminescence 12.30 pm Technology for aPL Testing Vittorio Pengo (Italy)

β2-Glycoprotein-I Domain-I in the Assessment of 12.45 pm Thrombosis Risk in APS Anisur Rahman (UK) Potential for Anti- Phosphatidylserine/Prothrombin Antibodies as a 1.00 pm Criteria Test Maria Laura Bertolaccini (UK) Lupus Anticoagulant Testing: The Value of Dilute Russell’s Viper Venom Time (dRVVT) and Silica 1.15 pm Clotting Time (SCT) Assays Armando Tripodi (Italy) * Sponsored by INOVA Diagnostics & Instrumentation Laboratory

SEPTEMBER 22, 2016 – THURSDAY AFTERNOON SESSIONS MAIN SESSION 3 DEEP DIVE SESSION 3 Mechanisms of Antiphospholipid Antibody-mediated Direct Oral Anticoagulants and Antiphospholipid Syndrome Pregnancy Morbidity Moderator Pier Luigi Meroni (Italy), Jane Moderator Ahmet Muzaffer Demir (Turkey), David Garcia s Salmon (USA) s (USA), Tom Ortel (USA) Room Hall A Room Hall B General Review – Mechanisms of General Review of Direct Oral Anticoagulants (DOACs) aPL-mediated Pregnancy Morbidity 1.30 pm 1.30 pm David Garcia (USA) Jane Salmon (USA)

Antiphospholipid Antibody RAPS – Rivaroxaban in Antiphospholipid Syndrome (APS) - Internalisation into the A prospective, randomized controlled phase II/III 1.50 pm Syncytiotrophoblast 2.00 pm clinical trial of rivaroxaban versus warfarin in patients Larry Chamley (New Zealand) with thrombotic antiphospholipid syndrome, with or without SLE Hannah Cohen (UK) RAPS – Rivaroxaban in APS Pilot Trial Update - A The Role of ApoER2 in aPL-mediated Multicenter Feasibility Study of Rivaroxaban for Patients Placental and Endothelial Dysfunction 2.10 pm 2.15 pm with APS and Prior Arterial or Venous Thrombosis Chieko Mineo (USA) Mark Crowther (Canada) TRAPS – Rivaroxaban in Thrombotic APS Trial Update - A Do Obstetric and Thrombotic aPL have Prospective, Randomized Clinical Trial Comparing Differential Effects Upon Target Cells? 2.30 pm 2.30 pm Rivaroxaban vs Warfarin in High Risk Patients With APS Ian Giles (UK) Vittorio Pengo (Italy) ASTRO APS - Apixaban for the Secondary Prevention of Targeting β -Glycoprotein-I to 2 Thromboembolism: A Prospective Randomized Outcome Prevent Obstetric APS 2.50 pm 2.45 pm Pilot Study Among Patients with APS Pier Luigi Meroni (Italy) Scott Woller (USA) 3.10 pm Group Conclusions 3.00 pm Group Discussion 3.15 pm Coffee Break, Exhibition, and 3.15 pm Coffee Break, Exhibition, and Poster Discussions 3.45 pm Poster Discussions 3.45 pm *Partially Sponsored by an Unrestricted Educational Grant from the Barbara Volcker Center for Women & Rheumatic Partially Sponsored by an Unrestricted Educational Grant from BAYER ® Diseases at Hospital for Special Surgery, New York,NY, USA

MAIN SESSION 4 – Abstract Recognition Award DEEP DIVE SESSION 4 - Disease Activity, Damage, Risk Scores, and (Innovation and Excellence) Presentations Quality of Life in APS Moderator Moderator Mary Carmen Amigo (Mexico), Ihsan Ertenli (Turkey), Graham Hughes (UK), Takao Koike (Japan) s s Savino Sciascia (Italy) Room Hall A Room Hall B OP01 - Gram Negative Bacterial Inflammation Ameliorated by the Plasma Introduction & the Importance of Damage and Risk Protein β -Glycoprotein-I 2 Measurement in APS 3.45 pm Bill Giannakopoulos (Australia), Saijun 3.45 pm Mary-Carmen Amigo (Mexico) Zhou, Gang Chen, Miao Qi1, Fatima El- Assaad, Steve A Krilis OP02 - Identification of Novel Genetic Susceptibility Loci in Primary APS Elizabeth Gensterblum, Travis Hughes, Manuel Martínez-Bueno, Maria Orietta Damage Index in APS 4.00 pm Borghi, Guillermo Pons-Estel, Gerard 4.00 pm Ma. Victoria Goycochea-Roblec (Mexico) Espinosa, Alexandra Zhernakova, Cisca Wijmenga, Ricard Cervera, Pier Luigi Meroni, Marta E Alarcón-Riquelme, Amr H Sawalha (USA) OP03 – Major Histocompatibility Complex Class II Alleles Influence Induction of Pathogenic aPL in a Thrombosis Mouse Model Antiphospholipid Score: A Quantitative Index for 4.15 pm Rohan Willis (USA), Elizabeth Papalardo, 4.15 pm Diagnosis of APS and Zurina Romay-Penabad, Premkumar Predictive Marker of Thrombosis. Christadoss, Chella David, Ana Laura Tatsuya Atsumi (Japan) Carrera-Marin, Elba Reyes-Maldonado, Rajani Rudrangi, Ethel Garcia-Latorre, Miri Blank, Allan R Brasier, Emilio B Gonzalez 4.30 pm OP04 - Antiphospholipid Syndrome 4.30 pm Global APS Score (GAPSS) Neutrophils are Characterized By Savino Sciascia (Italy) Overexpression of P-Selectin Glycoprotein Ligand 1, a Potential Therapeutic Target Jason S Knight (USA), Patrick Coit, He Meng, Srilakshmi Yalavarthi, Paul Renauer, Robert C Grenn, Levi F Mazza, Hui Wang, Daniel T Eitzman, Amr H Sawalha OP05 - Antiphospholipid Antibody- Mediated Increase of Tissue Factor in Arterial Wall is Associated with Increased 4.45 pm Thrombus Size in a Mouse Model 4.45 pm Can We Measure APS Disease Activity? Rohan Willis (USA), Pierre Grant, Zurina Anisur Rahman (UK) Romay-Penabad, Elizabeth Papalardo, Mohammed Jamaluddin, Rajani Rudrangi, Emilio Gonzalez, Allan R Brasier OP06 - Levels of Cell-bound C4d in Primary APS in Comparison to SLE Maria Gerosa (Italy), Paola Lonati, Quality of life in APS 5.00 pm Francesca Rovelli, Tania Ubiali, Paolo 5.00 pm Stephane Zuily (France) Macor, Maria Orietta Borghi, Pier Luigi Meroni OP07 - A Patient-derived Autoimmune IgG Type Monoclonal Anticardiolipin

Antibody that Binds to β2 Glycoprotein

Domain I but not to Total β2 Glycoprotein-I MoleculeKenji Oku (Japan), Group Discussion 5.15 pm Yuusaku Kanetsuka, Kazumasa Ohmura, 5.15 pm Masaru Kato, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita, Shinsuke Yasuda, Gary L Norman, Bas deLaat, Tatsuya Atsumi 5.30 pm Closure 5.30 pm Closure

SEPTEMBER 23, 2016 – FRIDAY MEET THE EXPERT SESSIONS Obstetric Difficult-to-treat Antiphospholipid Difficult-to-treat Antiphospholipid Antiphospholipid Antiphospholipid Syndrome Syndrome (Turkish) Antibodies/Syndrome & Lupus Syndrome 7-8 amGraham Hughes (UK) Doruk Erkan (USA) Paul Fortin (Canada) Ware Branch (USA) Room: TBD Room: TBD Room: TBD Room: TBD Antiphospholipid Digital Media for Antiphospholipid 12.30 pm Antibodies/Syndrome & Lupus Syndrome Education (Turkish) Laurent Phialy (France) Murat Inanc (Turkey) Room: TBD 1.30 pmRoom: TBD

SEPTEMBER 23, 2016 – FRIDAY MORNING SESSIONS MAIN SESSION 5 DEEP DIVE SESSION 5 Clinical and Prognostic Significance of “Criteria” and Interplay Between Lupus and Antiphospholipid Syndrome Non-Criteria Antiphospholipid Antibody Tests Moderator Tatsuya Atsumi (Japan), Maria Laura Moderator Paul Fortin (Canada), Michael Lockshin (USA), s Bertolaccini (UK), Gokhan Keser (Turkey) s Sule Yavuz (Turkey) Room Hall A Room Hall B General Overview and “Criteria” Introduction to Overlapping Diseases ELISA Tests 8.00 am 8.00 amMichael D. Lockshin (USA) Maria Laura Bertolaccini (UK) 8.20 am Lupus Anticoagulant Assay and Other 8.20 am Pathophysiological/Pathogenetic Interplay Between Tests That May Be Relevant to Lupus and APS Clinical Practice Pier Luigi Meroni (Italy) Ian Mackie (UK) Anti-phosphatidlyserine/antiprothrombin The Impact of aPL in Lupus Antibodies 8.40 am 8.40 amMurat Inanc (Turkey) Tatsuya Atsumi (Japan) Anti-Domain I Antibodies – A Specific and What Did We Learn From Hopkins Lupus Cohort About 9.00 am Predictive Marker of Thrombosis 9.00 am aPL/APS? Philip De Groot (Netherlands) Michelle Petri (USA) ARA (I&E) - OP08 - Which Test is the Best Predictor of Thrombosis in Patients with aPL and Associated Autoimmune Diseases? OP24 - Predictors of Thrombotic Events in Patients with Stéphane Zuily (France), Bas De Laat, SLE and aPL: a Prospective 10-year Follow-up 9.20 am Véronique Regnault, Pierre Kaminsky, 9.20 am Observational Study Hilde Kelchtermans, Zakera Shums, Roger Savino Sciascia (Italy), Anna Kuzenko, Irene Castagno, Albesa, Gary Norman, Philip G. De Groot, Massimo Radin, Laura Solfietti, Maria Tiziana Bertero Anne-Christine Rat, Jacques Ninet, Nadine Magy-Bertrand, Jean-Louis Pasquali, Marc Lambert, Bernard Lorcerie, Francis Guillemin, Denis Wahl 9.35 am Group Conclusions 9.25 am Group Conclusions 9.45 am Coffee Break, Exhibition, and Poster 9.45 am Coffee Break, Exhibition, and Poster Discussions 10.30 am Discussions 10.30 am

MAIN SESSION 6 DEEP DIVE SESSION 6 Definition and Epidemiology of Guidelines for Antiphospholipid Antibody Testing Antiphospholipid Syndrome Moderator Gulen Hatemi (Turkey), Roger Levy (Brazil), Moderator Maria Laura Bertolaccini (UK), Katrien Devreese (Belgium), s Denis Wahl (France) s Reyhan Diz-Kucukkaya (Turkey) Room Hall A Room Hall B Introduction and Overview of ISTH Lupus Anticoagulant Definition of APS Subcommittee Activities 10.30 amStephane Zuily (France) 10.30 am Bas de Laat (Netherlands) (Online Presentation) Definition of Obstetric APS Lupus Anticoagulant Testing Guidelines 10.50 amGuilherme De Jesus (Brazil) 10.50 amPhilip G de Groot (Netherlands) Definition of Catastrophic APS Solid Phase aPL ELISA Testing Guidelines 11.10 amRicard Cervera (Spain) 11.10 amKatrien Devreese (Belgium) The Significance of IgM Anticardiolipin and What Mimics APS? Anti-β -Glycoprotein-I Antibodies 11.30 amRoger Levy (Brazil) 11.30 am 2 Denis Wahl (France) The Significance of IgA Anticardiolipin and Epidemiology of APS Anti-β -Glycoprotein-I Antibodies 11.50 amMichael Lockshin (USA) 11.50 am 2 Angela Tincani (Italy) Conclusions and Future Collaboration Opportunities Group Conclusions 12.05 pm 12.10 pmMaria Laura Bertolaccini (UK) 12.15 pm 12.15 pm Lunch Break Lunch Break 1.30 pm 1.30 pm A Joint Session with International Society of Thrombosis and Hemostasis (ISTH) Lupus Anticoagulant Subcommittee SEPTEMBER 23, 2016 – FRIDAY NOON COMMITTEE MEETING Moderators Doruk Erkan (USA), Roger Levy (Brazil) Room TBD 12.15 pm International Congress on Antiphospholipid Antibodies 1.30 pm Executive Committee Meeting (by invitation only)

SEPTEMBER 23, 2016 – FRIDAY AFTERNOON SESSIONS MAIN SESSION 7 DEEP DIVE SESSION 7 Catastrophic Antiphospholipid Syndrome Pediatric Antiphospholipid Syndrome Task Force Report Moderator Ricard Cervera (Spain), Umut Kalyoncu Moderator Tadej Avcin (Slovenia), Barry Myones (USA) s (Turkey) s Room Hall A Room Hall B Catastrophic APS Task Force Report Introduction, Task Force Report, and Future Directions 1.30 pm Ricard Cervera (Spain) 1.30 pm Barry Myones (USA) ARA (YS) - OP18 - Catastrophic APS: Descriptive Analysis of 500 Patients from the 1.50 pm International CAPS Registry. 1.55 pm Neonatal APS and Beyond Ignasi Rodriguez-Pinto (Spain), Yehuda Cassyanne Aguiar (USA) Shoenfeld, Doruk Erkan, Gerard Espinosa Garriga, Ricard Cervera 2.05 pm How Do I Approach to Thrombotic Storm? 2.20 pm Pediatric APS Registries: Past, Present, and Future Tom Ortel (USA) Tadej Avcin (Slovenia) How Do I Approach to Catastrophic APS? Probing the North American Lupus Registries for APS Data 2.30 pm Ricard Cervera (Spain) 2.45 pm Arzu Soybilgic (USA) 2.55 pm ARA (I&E) - OP09 - Guideline for Diagnosis 3.10 pm Group Conclusions and Management of Catastrophic APS Kimberly Legault, Christopher Hillis, Elie Akl, Marc Carrier, Ricard Cervera, Mark Crowther (Canada), Doruk Erkan, Gerard Espinosa, Joerg Meerpohl, Karen Moffat, Sarah O'Brien, Vittorio Pengo, Jacob Rand, Ignasi Rodriguez- Pinto, Lisa Thom, Cindy Yeung, Alfonso Iorio, Holger Schunemann 3.10 pm Group Conclusions 3.15 Coffee Break, Exhibition, and 3.15 Coffee Break, Exhibition, and Poster Discussions 3.45 Poster Discussions 3.45 *In Memory of Ron Asherson and Josep Font

MAIN SESSION 8 DEEP DIVE SESSION 8 Pediatric Antiphospholipid Syndrome Abstract Recognition Award (Young Scholar) Presentations Moderator Tadej Avcin (Slovenia), Barry Myones (USA), Moderator Nigel Harris (Jamaica), Jason Knight (USA) s Seza Ozen (Turkey) s Room Hall A Room Hall B OP12 - Longitudinal Human Gut Microbial Community Profiling in PS Reveals Enrichment of a Developmental Hemostasis Cardiolipin-producing Taxon 3.45 pm Patti Massicotte (Canada) 3.45 pm Cassyanne L. Aguiar (USA), William Ruff, Andrew Goodman, Doruk Erkan, Martin A. Kriegel OP13 - A Type I Interferon Signature in Monocytes and Thrombotic and Non-thrombotic Decreased Levels of irculating Plasmacytoid Dendritic Cells in Neurological Manifestations in Patients with Primary APS 4.05 pm Children with aPL 4.00 pm Lucas L van den Hoogen (Netherlands), Ruth DE Fritsch-Stork, Ann Yeh (Canada) Marjan A Versnel, Joel AG van Roon, Timothy RDJ Radstake OP14 - Signaling by Mammalian Target of Rapamycin Should We Treat Children with APS (mTORC) Highlight Pathological IgG and 4.25 pm Differently? 4.15 pm IgA in Systemic Lupus Erythematosus Patients with Secondary APS Gili Kenet (Israel) (Online Presentation) Vinicius Domingues (USA), Robert Clancy, Sara Rasmussen, H Michael Belmont 4.45 pm OP25 - Evidence Based Recommendations 4.30 pm OP15 - Circulating Immune Complexes of IgA Bound to β2- for Diagnosis and Treatment of the APS in Glycoprotein I are a Predictive Marker for Graft Loss in Children - Results of the Share Initiative Patients Positive for IgA aβ2GPI Jose Angel Martinez-Flores (Spain), Manuel Serrano, Oscar Tadej Avcin (Slovenia), Noortje Groot, Nienke Cabrera, Dolores Perez, Margarita Sevilla, Sergio Mora, de Graeff, Brigitte Bader-Meunier, Paul Florencio Garcia, Jose Maria Morales, Antonio Serrano Brogan, Pavla Dolezalova, Brian Feldman, Isabelle Kone-Paut, Pekka Lahdenne, Alberto Martini, Liza McCann, Seza Ozen, Clarisa Pilkington, Angelo Ravelli, Annet van Royen, Nico Wulffraat, Sylvia Kamphuis, Michael Beresford OP16 - Development of New International Classification Criteria for APS: Phase I Item Generation Survey- Part A Long-term Follow-up of Children Born to Medha Barbhaiya (USA), Karen Costenbader, Francis 5.00 pm Mothers with APS 4.45 pm Laura Andreoli (Italy) Guillemin, Ray Naden, Stephane Zuily, Doruk Erkan on Behalf of the 15th International Congress on aPL, APS Classification Criteria Task Force OP17 - Thrombotic, Hemorrhagic and Obstetrical Outcomes During Pregnancy and the Post-Partum Period In APS Cécile Marie Yelnik (France), Nathalie Costedoat-Chalumeau, 5.20 pm Group Conclusions 5.00 pm Véronique Le Guern, Jean-Louis Bacri, Marta Guerra, Geoffrey Urbanski, Nathalie Morel, Gaëlle Guettrot-Imbert, David Launay, Eric Hachulla, Pierre-Yves Hatron, Jane E Salmon, Marc Lambert 5.15 pm Award Ceremony 5.30 pm Closure 5.30 pm Closure *In Memory of Silvia Pierangeli and Aziz Gharavi

SEPTEMBER 24, 2016 – SATURDAY MEET THE EXPERT SESSIONS Catastrophic Pediatric Pediatric 7-8 Catastrophic Antiphospholipid Syndrome Antiphospholipid Antiphospholipid Antiphospholipid Ricard Cervera (Spain) Syndrome (Turkish) Syndrome Syndrome (Turkish) amRoom: TBD Doruk Erkan (USA) Tadej Avcin (Slovenia) Arzu Soybilgic (USA) Room: TBD Room: TBD Room: TBD

SEPTEMBER 24, 2016 – SATURDAY MORNING SESSIONS MAIN SESSION 9 DEEP DIVE SESSION 9 Prevention and Treatment of Thrombotic Natural Proteins Involved in Antiphospholipid Syndrome Antiphospholipid Syndrome: Moderator Mark Crowther (Canada), Doruk Erkan (USA), Moderator Philip G de Groot (Netherlands), Steve Krilis (Australia) s Vedat Hamuryudan (Turkey) s Room Hall A Room Hall B General Review - Primary Thrombosis Introduction & General Review Prevention 8.00 am 8.00 am Philip G de Groot (Netherlands) Doruk Erkan (USA) General Review – Secondary Thrombosis The Structure and Post-Translational Modification of 8.20 am Prevention 8.20 am β2-Glycoprotein-I Mark Crowther (Canada) Steve Krilis (Australia) Importance of Cardiovascular Reimagining APS Through the Door of Imaging: The Role of 8.40 am Disease Prevention in APS 8.40 am Macro-immune Complexes in APS Ian Bruce (UK) Jacob Rand (USA) Can we Stop Anticoagulation in APS Patients Small angled X-ray Scattering of β -Glycoprotein-I with Previous Thrombosis? 2 9.00 am 9.00 amBas de Laat (Netherlands) (Online Presentation) David Garcia (USA) Hydroxychloroquine in APS – Platelet-derived Chemokine and Endothelial Cell Interaction 9.20 am Where do we stand? 9.20 am in APS Maria G. Tektonidou (Greece) Panayiotis Vlachoyiannopoulos (Greece) 9.40 am Group Conclusions 9.40 am Group Conclusions 9.45 am Coffee Break, Exhibition, and Poster 9.45 am Coffee Break, Exhibition, and Poster Discussions 10.30 am Discussions 10.30 am MAIN SESSION 10 DEEP DIVE SESSION 10 Prevention & Treatment of Obstetric New Generation Antiphospholipid Antibody Tests Antiphospholipid Syndrome Moderator Ware Branch (USA), Guilherme De Jesus Moderator Maria Laura Bertolaccini (UK), Bahar Artim Esen (Turkey) s (Brazil) s Room Hall A Room Hall B

Assessment of Fetal Death - The Role of Anti-β2-Glycoprotein-I/HLA class II Complex 10.30 am aPL and Other Confounding Factors 10.30 am Antibodies in APS Robert Silver (USA) Hisashi Arase (Japan) What is the Impact of Treatment in Anti-Domain IV/V Antibodies 10.55 am Obstetric APS? 10.50 am Pier Luigi Meroni (Italy) Ware Branch (USA) ARA (I&E) – OP10 - Antiphospholipid Antibodies in Women with Preterm Annexin A5 Resistance Assay and Delivery for Preeclampsia or 11.20 am 11.10 am Alternative Functional Assays Placental Insufficiency (PREPI) Jacob Rand (USA) Karen J. Gibbins (USA), Anne E. Tebo, Samantha Nielsen, D. Ware Branch ARA (I&E) – OP11 - Recurrent Pregnancy Loss in Women with and without aPL Karen J. Gibbins (USA), Lindsey A. Sjaarda, Thrombin Generation Tests for Functional Effects of aPL 11.35 am D. Ware Branch, Sunni L. Mumford, Neil J. 11.30 amDenis Wahl (France) Perkins, Enrique F. Schisterman, Robert M. Silver OP26 - Beneficial Effects of Pravastatin in the Management of Obstetric APS Refractory to Antithrombotic Therapy Anti-Factor X Antibodies 11.50 pm Eleftheria Lefkou, Apostolos Mamopoulos, 11.45 amBahar Artim Esen (Turkey) Themistoklis Dagklis, Christos Vosnakis, David Rousso, Guillermina Girardi (UK) APhL Enzyme-linked Immunosorbent Assay (ELISA) 12.05 pm Group Conclusions 12.00 pmRohan Willis (USA)

12.15 pm 12.15 pm Lunch Break & Satellite Symposium Lunch Break & Satellite Symposium 1.30 pm 1.30 pm

SEPTEMBER 24, 2016 – SATURDAY PATIENT WORKSHOP Antiphospholipid Syndrome and Systemic Lupus Erythematosus English Joann Vega (USA) Room: Moderators Turkish Ayten Yazici (Turkey) Room: Bahar Artim Esen (Turkey), Doruk Erkan (USA), Murat Speakers Inanc (Turkey), Arzu Soybilgic (USA) 10.30 am Introduction 12.15 pm

Basic Immunology for Antiphospholipid Syndrome & Lupus Patients

Antiphospholipid Syndrome & Lupus:

 Clinical Manifestations

 Kidney Disease  Management

 Damage and Prevention Strategies

 Pregnancy

 Importance of Drug Adherence

Pediatric Antiphospholipid Syndrome & Lupus

Questions & Answers Sponsored by an Educational Grant from Creaky Joints

SEPTEMBER 24, 2016 – SATURDAY NOON SATELLITE SYMPOSIUM Antiphospholipid Syndrome and Systemic Lupus Erythematosus Moderators Doruk Erkan (USA), Murat Inanc (Turkey) Room Hall A Introduction 12.15 pm Doruk Erkan (USA), Murat Inanc (Turkey) Are There Lessons Learned from Lupus Clinical Trials 12.30 pm that are Applicable to Antiphospholipid Syndrome? Richard Furie (USA) 1.15 pm Questions & Answers Sponsored by an Unrestricted Educational Grant from GSK

SEPTEMBER 24, 2016 – SATURDAY AFTERNOON SESSIONS MAIN SESSION 11 DEEP DIVE SESSION 11 Management of Non-Criteria Manifestations in Antiphospholipid Syndrome Classification Criteria Task Antiphospholipid Syndrome Force Report Moderator Danieli Andrade (Brazil), Richard Furie (USA), Moderator Doruk Erkan (USA), Sedat Kiraz (Turkey), s Michelle Ugolini (Brazil) s Stephane Zuily (France) Room Hall A Room Hall B 1.30 pm Antiphospholipid Antibody Nephropathy Sapporo APS Classification Criteria: Historical Perspective Case Presenter: Maria G. Tektonidou (Greece) 1.30 pm Takao Koike (Japan) Expert Opinion: Maria G. Tektonidou (Greece) 1.55 pm Severe Thrombocytopenia Strengths and Limitations of Updated Sapporo APS Case Presenter: Michelle Ugolini (Brazil) 1.50 pm Classification Criteria Expert Opinion: Reyhan Diz Kucukkaya (Turkey) Ronald Derksen (Netherlands) 2.20 pm Cardiac Valve Disease 14th International Congress on aPL Task Force Report on Presenter: Ozan Unlu (Pre-recorded, USA) 2.10 pm “Non-criteria” Clinical Manifestations Expert Opinion: Mary Carmen Amigo (Mexico) Roger Levy (Brazil) 2.45 pm Skin Ulcers 15th International Congress on aPL New APS Classification Presenter: Michelle Ugolini (Brazil) 2.30 pm Criteria Initiative – Where Do We Stand? Expert Opinion: Kurosh Parsi (Australia) Doruk Erkan (USA) Meta-analyses in APS: What Do We Know and How Do 3.10 pm Group Conclusions 2.50 pm They Help Us Develop New Classification Criteria? Denis Wahl (France) 3.10 pm Group Conclusions 3.15 Coffee Break, Exhibition, and 3.15 Coffee Break, Exhibition, and Poster Discussions 3.45 Poster Discussions 3.45

MAIN SESSION 12 DEEP DIVE SESSION 12 Neuropsychiatric Antiphospholipid Syndrome Oral (Podium) Abstract Presentations Moderator Servet Akar (Turkey), Maria Laura Bertolaccini Moderator Ali Akdogan (Turkey), Anisur Rahman (UK) s (UK), Doruk Erkan (USA) s Room Hall A Room Hall B OP19 - The First Genome-Wide Association Study Identifying TSHR as A New Susceptibility Locus for Obstetric APS Antiphospholipid Antibodies & Brain: Mayumi Sugiura-Ogasawara (Japan), Yosuke Omae, Minae 3.45 pm Neuroimaging Findings 3.45 pm Kawashima, Licht Toyo-oka, Seik-Soon Khor, Hiromi Sawai, Simone Appenzeller (Brazil) Tetsuya Horita, Tatsuya Atsumi, Atsuko Murashima, Tamao Kitaori, Kinue Katano, Yasuhiko Ozaki, Katsushi Tokunaga Antiphospholipid Antibodies & Brain: PP044 (Late-breaking Abstract) - PEGylated DI Inhibits Non-vascular Manifestations & Thrombosis in a Mouse Model of APS 4.05 pm Treatment Options 4.00 pm Thomas Christopher Richard McDonnell, Rohan Willis, Giovanni Sanna (UK) Charis Pericleous, Zurina Romay-Penabad, Ian Giles, Yiannis Ioannou, Elizabeth Papalardo, Anisur Rahman (UK) Antiphospholipid Antibodies & Cognitive OP20 - Early Endosome as a Potential Target for Dysfunction: Clinical Perspectives Phosphatidylethanolamine-Binding Agents 4.25 pm 4.15 pm Songwang Hou, Heike Folsch, Steven E Johnson, Ke Elizabeth Kozora (USA) Ke, Ming Zhao (USA) OP21 - The Clinical Relevance of Antibodies Against Antiphospholipid Antibodies & Cognitive Domain 1 and Domain 4/5 of β2 Glycoprotein I in Dysfunction: Potential Mechanisms and Obstetric APS the Effect of aPL in Mouse Fetal Brain Cecilia Beatrice Chighizola (Italy), Laura Andreoli, Marta 4.45 pm Development 4.30 pm Tonello, Maria Gabriella Raimondo, Francesca Pregnolato, Cecilia Nalli, Elena Mattia, Laura Cesana, Rajesh Kumar, Guillermina Girardi (UK) Chiara Comerio, Claudia Grossi, Francesco Mombelli, Maria Gerosa, Maria Orietta Borghi, Amelia Ruffatti, Angela Tincani, Pier Luigi Meroni OP22 – Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein I are Strongly Associated with The Occurrence of Acute Thrombotic Events 5.05 pm Group Conclusions 4.45 pm Jose Angel Martinez-Flores (Spain), Oscar Cabrera, Manuel Serrano, Dolopres Perez, Margarita Sevilla Sergio Mora, Rosa Ayala, Luis Morillas, Jose Maria Morales, Antonio Serrano OP23 - Circulating Endothelial Cells Can Identify Patients with Antiphospholipid-Antibodies at Risk for Thrombosis 5.00 pm Stéphane Zuily (France), Marie Heymonet, Tu Qian, Marcelo De Carvalho, Gilbert Faure, Denis Wahl 5.15 5.15 Congress Closing Remarks Congress Closing Remarks 5.30 5.30